GLPG0259: Phase II started

Galapagos began a 12-week, double-blind, placebo-controlled, European Phase II trial to evaluate 3 doses of oral GLPG0259 plus once-daily methotrexate in 180 patients. J&J's Janssen Pharmaceutica N.V....